The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis

The VAD (vincristine-doxorubicin-dexamethasone) regimen has been used for decades to treat multiple myeloma (MM). Based on reports that vascular endothelial growth factor- (VEGF-) mediated angiogenesis is critical for MM pathogenesis, the antiangiogenic compound thalidomide has been added to VAD (T-...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Gan-Lin, Xu, Duo-Rong, Zou, Wai-Yi, He, Sui-Zhi, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252213/
https://www.ncbi.nlm.nih.gov/pubmed/30534560
http://dx.doi.org/10.1155/2018/3936706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252213/
https://www.ncbi.nlm.nih.gov/pubmed/30534560
http://dx.doi.org/10.1155/2018/3936706

Ejemplares similares